After Leqembi Approval, US FDA In No Rush To Declare Amyloid A Validated Surrogate Endpoint

 
• By Sue Sutter
Clock in sand
US FDA likely to take its time in making a validation decision about amyloid reduction as a surrogate endpoint. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards